Some safety aspects of generic prescribing

International Journal of Risk and Safety in Medicine

Volumn 16, Issue 3, 2004, Pages 191-194

  Van Boxtel, Chris J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH ECONOMICS; HUMAN; NETHERLANDS; PRESCRIPTION; PUBLIC HEALTH; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 21444457089     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. D.W. Bates, Costs of drug-related morbidity and mortality: enormous and growing rapidly, J. Am. Pharm. Assoc. 41 (2001), 156-157.
2. W.B.F. Brouwer and F.F.H. Rutten, Een gouden pil voor apothekers, Medisch Contact 57 (2002), 737-740.
3. F.R. Ernst and A.J. Grizzle, Drug-related morbidity and mortality: updating the cost-of-illness model, J. Am. Pharm. Assoc. 41 (2001), 192-199.
4. D. Even-Adin, J.A. De Muylder and J. Sternon, Generics: similarities, bioequivalence but no conformity, J. Pharm. Belg. 57 (2000), 14-20.
5. E.A. Flynn, K.N. Barker, G.A. Pepper, D.W. Bates and R.E. Mikeal, Comparison of methods for detecting medication errors in 36 hospitals and skilled-nursing facilities, Am. J. Health-Syst. Pharm. 59 (2002), 436-446.
6. E. Grandia, Valkuilen bij generiek voorschrijven, Medisch Contact 55 (2000), 737.
7. W.W. Hauck and S. Anderson, Types of bioequivalence and related statistical considerations, Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992), 181-187.
8. A. Hollis, The importance of being first: evidence from Canadian generic pharmaceuticals, Health Econ. 11 (2002), 723-734.
9. K. de Joncheere, A.D. Rietveld and C. Huttin, Experiences with Generics, Int. J. Risk Safety Med. 15 (2002), 101-109.
10. J. Lexchin, The effect of generic competition on the price of brand-name drugs, Health Policy 68 (2004), 47-54.
11. A. Marzo, Open questions on bioequivalence: some problems and some solutions, Pharmacol. Res. 40 (1999), 357-368.
12. P.A. Meredith, Generic drugs. Therapeutic equivalence [Review], Drug Safely 15 (1998), 233-242.
13. R. Mofsen and J. Balter, Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation, Clin. Ther. 23 (2001), 1720-1731.
14. K. Nakai, M. Fujita and H. Ogata, New bioequivalence studies: individual bioequivalence and population bioequivalence, Yakugaku Zasshi 120 (2000), 1201-1208.
15. M. Spino, Y.C. Tsang and R. Pop, Dissolution and in vivo evidence of differences in reference products: impact on development of generic drugs, Eur. J. Drug. Metab. Pharmacokinet. 25 (2001), 18-24.
16. S. de Vries, De tragiek achter generiek, Medisch Contact 57 (2002), 1059.
17. WHO, How to Develop and Implement a National Drug Policy, 2nd edn, World Health Organization. Geneva, 2001.
18. W.M. Wiersinga, Thyroid hormone replacement therapy, Horm. Res. 56(Suppl. 1) (2002), 74-81.
19. H.P. Wijnand, De waarde van casuïstiek, Medisch Contact 58 (2003), 657-659.